Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBH589 in low or intermediate-1 risk MDS
NCT00939159Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2009
- Primary completion
- Jun 2013
- Countries
- 1
01
Overview
A Phase 2 trial of panobinostat in myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2009; status: terminated.
02
Drugs
panobinostat
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00939159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00939159.